Surmodics Inc stock (US88025U1097): shares steady on Nasdaq as investors look to recent quarterly trends

Surmodics stock traded largely unchanged on Nasdaq on 06/02/2026, as the U.S.-based medical technology company remains in focus following its latest reported quarterly results and ongoing developments in its vascular intervention and in vitro diagnostics businesses.

Surmodics shares traded on the Nasdaq in the United States were broadly stable on 06/02/2026, with the stock changing hands in regular volumes and showing no outsized price swing compared with recent sessions, according to Nasdaq price data as of that date.

The stock traded at a level close to its recent range in USD on Nasdaq under the ticker SRDX on 06/02/2026, underscoring that investors are still digesting the company’s most recently reported quarterly figures and its ongoing strategic focus on vascular intervention and in vitro diagnostics, according to Nasdaq trading data as of that date.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: SRDX
• Sector/industry: Medical technology and diagnostics
• Headquarters/country: Eden Prairie, United States
• Core markets: United States and international cardiovascular and diagnostics markets
• Key revenue drivers: Vascular intervention devices and in vitro diagnostic technologies
• Home exchange/listing venue: Nasdaq (SRDX)
• Trading currency: USD

Surmodics Inc: core business model

Surmodics focuses on developing and supplying medical device technologies and finished products for vascular intervention alongside specialized chemistries and components used by in vitro diagnostics manufacturers to build their test systems.

Latest quarterly results for Surmodics Inc at a glance

In its most recently reported quarter, Surmodics disclosed financial results that highlighted the contribution of its vascular intervention and in vitro diagnostics segments to overall revenue, according to the company’s latest quarterly report filed with the U.S. Securities and Exchange Commission.

The company’s recent filing showed that revenue growth and operating performance were influenced by product sales and development revenue in its vascular intervention portfolio as well as demand for its in vitro diagnostics reagents, according to the same SEC disclosure.

Conclusion

The largely unchanged Surmodics share price on Nasdaq on 06/02/2026 points to a market still weighing the company’s most recent quarterly metrics and the balance between its vascular intervention and in vitro diagnostics activities.

How the company executes on its medical technology pipeline and commercial strategy in the United States and other key markets will likely shape investor discussion around future quarterly results and trading in SRDX over time.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.